Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05146089 · ClinicalTrials.gov registry record · Early Phase 1
Reflex Responses to Intermittent Hypoxia in Humans: Mechanisms and Consequences
A Early Phase 1 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 54
- Enrollment target
NCT05146089: Completed Early Phase 1 study, sponsored by University of Missouri-Columbia.
NCT05146089 is a Early Phase 1 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 54 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05146089, a Early Phase 1 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The overall goal of this project is to better understand the effect of intermittent hypoxia (IH) on sympathetic neuronal discharge patterns in humans, as well as mechanisms that mediate persistent sympathoexcitation with IH.
Primary Outcome
MSNA burst incidence (bursts/100 heart beats)
Interventions
- OTHER Hypoxic exposure
- OTHER modified Oxford test
- DRUG Oral Bosentan 62.5 mg
- OTHER Hypoxic ventilatory response test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2016-12-20 |
| Est. Completion | 2021-04-12 |
| Phase | Early Phase 1 |
What the finished NCT05146089 record still lists
NCT05146089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Hypoxic exposure is the first listed.
NCT05146089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05146089 about?
NCT05146089 is a clinical study titled "Reflex Responses to Intermittent Hypoxia in Humans: Mechanisms and Consequences". The overall goal of this project is to better understand the effect of intermittent hypoxia (IH) on sympathetic neuronal discharge patterns in humans, as well as mechanisms that mediate persistent sympathoexcitation with IH.
What is the current status of trial NCT05146089?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 54 participants. The study started on 2016-12-20. Estimated completion is 2021-04-12.
What interventions are being tested in trial NCT05146089?
The interventions under investigation include: Hypoxic exposure (OTHER), modified Oxford test (OTHER), Oral Bosentan 62.5 mg (DRUG), Hypoxic ventilatory response test (OTHER).
Who is sponsoring clinical trial NCT05146089?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05146089's enrollment target sits among peer trials
54 464th of 2000 higher than 1,530 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI